外周T细胞淋巴瘤非特指型中RORγt免疫组化表达的临床病理分析
提示RORγt阳性PTCL-NOS可能为其一个亚群。
要点
- PTCL-NOS中RORγt阳性率为17.6%(30/170)。
- RORγt阳性与CD8阳性、低白细胞及中性粒细胞计数相关。
- RORγt阳性者完全缓解率更高,总生存有更好趋势。
核心结论
- RORγt阳性PTCL-NOS可能构成PTCL-NOS的一个亚群。
- 需在转录水平进一步研究相关基因组异常以确认结果。
研究设计与样本
- 对170例PTCL-NOS病例进行免疫组化确认RORγt表达并开展病理与临床分析。
主要发现
- RORγt阳性病例占17.6%(30/170)。
临床怎么用
- RORγt免疫组化可辅助识别PTCL-NOS中具有特定临床病理特征的亚群。
局限性
- 需进一步在转录水平研究相关基因组异常以确认本研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is cytologically and phenotypically heterogeneous. Retinoic acid-related orphan receptor-γt (RORγt) is a transcription factor that regulates the differentiation of naïve CD4+ helper T cells to Th17 cells. In the present study, we immunohistochemically confirmed the expression of RORγt in PTCL-NOS. Pathological and clinical investigations were performed for 170 cases of PTCL-NOS. RORγt-positive cases accounted for 17.6% (30/170) of the total cases, and they showed a significantly higher frequency of CD8 positivity (P = .033), lower counts of white blood cells (P = .030) and neutrophils (P = .039) in the peripheral blood, higher levels of hypergammaglobulinemia (P = .031), a higher frequency of a complete response (P = .009), and a tendency for a lower International Prognostic Index (P = .061) and better overall survival (P = .0806). These results suggest that RORγt-positive PTCL-NOS could be a subpopulation of PTCL-NOS. Further research associated with this genomic abnormality at the transcriptional level is needed to confirm the results of this study.
引用
- Yanagida E, Miyoshi H, Kawamoto K, et al. Clinicopathological analysis of immunohistochemical expression of retinoic acid-related orphan receptor-γt in peripheral T-cell lymphoma, not otherwise specified. Hum Pathol. 2018. PMID: 29775622. doi:10.1016/j.humpath.2018.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。